During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

UnitedHealth Group Incorporated (NYSE:UNH)

  • Dividend Yield: 3.38%
  • Mizuho analyst Ann Hynes maintained an Outperform rating and cut the price target from $430 to $350 on Feb. 5, 2026. This analyst has an accuracy rate of 69%
  • Truist Securities analyst David Macdonald maintained a Buy rating and slashed the price target from $410 to $370 on Feb. 2, 2026. This analyst has an accuracy rate of 66%.
  • Recent News: On March 2, UnitedHealth Group filed shelf prospectus for offering of securities.
  • Benzinga Pro’s real-time newsfeed alerted to latest UNH news.

Viatris Inc. (NASDAQ:VTRS)

  • Dividend Yield: 3.71%
  • Barclays analyst Glen Santangelo maintained an Overweight rating and raised the price target from $15 to $17 on March 24, 2026. This analyst has an accuracy rate of 52%.
  • Piper Sandler analyst David Amsellem maintained a Neutral rating and increased the price target from $9 to $12 on Jan. 28, 2026. This analyst has an accuracy rate of 75%
  • Recent News: On Feb. 26, Viatris reported fourth-quarter financial results and issued FY26 adjusted EPS guidance below estimates.
  • Benzinga Pro's real-time newsfeed alerted to latest VTRS news

CVS Health Corporation (NYSE:CVS)

  • Dividend Yield: 3.79%
  • B of A Securities analyst Michael Cherny maintained a Buy rating and cut the price target from $100 to $95 on Jan. 27, 2026. This analyst has an accuracy rate of 69%.
  • JP Morgan analyst Lisa Gill maintained an Overweight rating and raised the price target from $93 to $101 on Dec. 17, 2025. This analyst has an accuracy rate of 52%.
  • Recent News: On Feb. 10, the company reported fourth-quarter sales of $105.69 billion, beating the consensus of $103.59 billion.
  • Benzinga Pro’s real-time newsfeed alerted to latest CVS news

Photo via Shutterstock